PL2056874T3 - Leczenie nowotworu przeciwciałem przeciw VEGF - Google Patents

Leczenie nowotworu przeciwciałem przeciw VEGF

Info

Publication number
PL2056874T3
PL2056874T3 PL07786693T PL07786693T PL2056874T3 PL 2056874 T3 PL2056874 T3 PL 2056874T3 PL 07786693 T PL07786693 T PL 07786693T PL 07786693 T PL07786693 T PL 07786693T PL 2056874 T3 PL2056874 T3 PL 2056874T3
Authority
PL
Poland
Prior art keywords
vegf antibody
tumor therapy
tumor
therapy
vegf
Prior art date
Application number
PL07786693T
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2056874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2056874T3 publication Critical patent/PL2056874T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL07786693T 2006-08-21 2007-08-17 Leczenie nowotworu przeciwciałem przeciw VEGF PL2056874T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
EP07786693A EP2056874B1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (1)

Publication Number Publication Date
PL2056874T3 true PL2056874T3 (pl) 2013-02-28

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07786693T PL2056874T3 (pl) 2006-08-21 2007-08-17 Leczenie nowotworu przeciwciałem przeciw VEGF

Country Status (28)

Country Link
US (6) US20080050385A1 (pl)
EP (2) EP2056874B1 (pl)
JP (3) JP2010501498A (pl)
KR (1) KR101136763B1 (pl)
CN (1) CN101505792B (pl)
AR (1) AR062419A1 (pl)
AU (1) AU2007287794B2 (pl)
BR (1) BRPI0715829A2 (pl)
CA (1) CA2660681A1 (pl)
CL (1) CL2007002404A1 (pl)
CO (1) CO6150193A2 (pl)
CR (1) CR10590A (pl)
DK (1) DK2056874T3 (pl)
ES (2) ES2546066T3 (pl)
IL (2) IL196810A0 (pl)
MA (1) MA30654B1 (pl)
MX (1) MX2009001715A (pl)
MY (1) MY150756A (pl)
NO (1) NO20090450L (pl)
NZ (1) NZ574580A (pl)
PE (1) PE20080911A1 (pl)
PL (1) PL2056874T3 (pl)
RU (1) RU2528884C2 (pl)
SG (1) SG174090A1 (pl)
SI (1) SI2056874T1 (pl)
TW (2) TW200825106A (pl)
WO (1) WO2008022746A1 (pl)
ZA (1) ZA200901200B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
RS53594B1 (sr) * 2004-07-22 2015-02-27 Genentech, Inc. Preparat her2 antitela
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518086A (pt) * 2004-12-07 2008-10-28 Genentech Inc métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
MX2007009889A (es) 2005-02-23 2007-09-07 Genentech Inc Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2056874B1 (en) * 2006-08-21 2012-09-19 F. Hoffmann-La Roche AG Tumor therapy with an anti-vegf antibody
ES2477497T3 (es) 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
CA2804348A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
JP2015502543A (ja) * 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
LT3589661T (lt) 2017-03-02 2024-02-12 Genentech, Inc. Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
JP2020517273A (ja) 2017-04-24 2020-06-18 ジェネンテック， インコーポレイテッド 膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
US20230330094A1 (en) * 2020-09-04 2023-10-19 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination compositions and methods for treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
CA2269204C (en) 1996-10-18 2012-01-24 Genentech, Inc. Anti-erbb2 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
JP3495706B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU1687500A (en) 1998-12-16 2000-07-03 Kyowa Hakko Kogyo Co. Ltd. Antihuman vegf monoclonal antibody
BR0008202A (pt) 1999-02-11 2002-02-19 Pfizer Prod Inc Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
PL203326B1 (pl) 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003222252A1 (en) 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
WO2005000090A2 (en) 2003-05-30 2005-01-06 Medi-Screw, Inc. Medical implant systems
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2004261980A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
EP1789446A2 (en) * 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
RU2418004C2 (ru) * 2004-10-04 2011-05-10 Дженентек, Инк. Модуляторы активатора фактора роста гепатоцитов
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2056874B1 (en) * 2006-08-21 2012-09-19 F. Hoffmann-La Roche AG Tumor therapy with an anti-vegf antibody
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
NO20090450L (no) 2009-02-27
AU2007287794A1 (en) 2008-02-28
TW200825106A (en) 2008-06-16
EP2441472A1 (en) 2012-04-18
US20100285010A1 (en) 2010-11-11
DK2056874T3 (da) 2012-10-15
IL196810A0 (en) 2011-08-01
CN101505792A (zh) 2009-08-12
PE20080911A1 (es) 2008-08-15
US20180251536A1 (en) 2018-09-06
ZA200901200B (en) 2013-08-28
US20080050385A1 (en) 2008-02-28
AU2007287794B2 (en) 2013-03-28
TW201107346A (en) 2011-03-01
EP2441472B1 (en) 2015-06-10
ES2392630T3 (es) 2012-12-12
SG174090A1 (en) 2011-09-29
KR20090032136A (ko) 2009-03-31
US20150239969A1 (en) 2015-08-27
US20130183292A1 (en) 2013-07-18
CN101505792B (zh) 2012-10-03
NZ574580A (en) 2011-12-22
KR101136763B1 (ko) 2012-04-24
CO6150193A2 (es) 2010-04-20
RU2009110102A (ru) 2010-09-27
CA2660681A1 (en) 2008-02-28
JP2010501498A (ja) 2010-01-21
CL2007002404A1 (es) 2008-04-18
JP2013163687A (ja) 2013-08-22
MX2009001715A (es) 2009-02-25
IL238045A0 (en) 2015-05-31
SI2056874T1 (sl) 2012-12-31
ES2546066T3 (es) 2015-09-18
CR10590A (es) 2009-03-20
AR062419A1 (es) 2008-11-05
MA30654B1 (fr) 2009-08-03
RU2528884C2 (ru) 2014-09-20
HK1134441A1 (en) 2010-04-30
EP2056874B1 (en) 2012-09-19
MY150756A (en) 2014-02-28
WO2008022746A1 (en) 2008-02-28
JP2015214582A (ja) 2015-12-03
BRPI0715829A2 (pt) 2013-07-23
US20110223159A1 (en) 2011-09-15
EP2056874A1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
IL238045A0 (en) Tumor treatment with an antibody against vegf
IL205547A0 (en) Anti-vegf antibody compounds and methods
IL229512A (en) Anti-vegf antibodies
IL200437A0 (en) Anti-sclerostin antibodies
SI2195026T1 (sl) Protitelesa proti sklerostinu
PL2242773T3 (pl) Przeciwciała monoklonalne do leczenia nowotworu
IL243376A0 (en) Antagonistic antibody against epha2 for cancer treatment
IL186662A0 (en) Combination cancer therapy with
IL179891A0 (en) Tumor specific antibody
ZA201104110B (en) Antibodies that specifically block the biological activity of a tumor antigen
EP2331134A4 (en) ANTI-PANCREAS CANCER ANTIBODY
ZA200900954B (en) Ant-C5aR antibodies with improved properties
IL186980A0 (en) Characterizing prostate cancer
GB0815788D0 (en) Therapeutic antibodies
IL198354A0 (en) Genetic variations associated with tumors
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy
AU2006905191A0 (en) Antibody therapy
HK1157353A (en) Anti-pamp therapeutic antibodies
AU2006905591A0 (en) Tumour selective antibody
IL207478A0 (en) Monoclonal antibodies for tumor treatment
GB0612259D0 (en) Cancer therapeutic
GB0606702D0 (en) Cancer therapeutic
GB0604689D0 (en) The cure for cancer